WASHINGTON--(BUSINESS WIRE)--

Today, the Biotechnology Industry Organization (BIO) praised Sen. Kay Hagan (D-NC) for introducing the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act. The following statement can be attributed to BIO President and CEO Jim Greenwood:

“The Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act will help unleash the promise of biotechnology to speed life-saving cures, novel medicines and scientific breakthroughs to patients living with debilitating diseases such as cancer, HIV/AIDS, Parkinson’s and diabetes.

“The TREAT Act will help break the institutional barriers to a faster idea-to-market pathway and speed new cures to patients most desperately in need. Through this bill, Senator Hagan has offered renewed hope to patients desperately in need of cures and breakthrough new medicines as well as a boost to our nation’s economy. The legislation will help the U.S. Food and Drug Administration (FDA) retain its leadership position as the global ‘gold standard’ for regulatory science and consumer protection.

“This bill will modernize the FDA and allow the agency to keep up with the fast pace of American scientific breakthroughs. Further, it will ensure a transparent and more predictable pathway for the development of safe and effective next generation medicines and cures while maintaining U.S. leadership in biomedical innovation. A more streamlined and forward-thinking regulatory review process will ensure that innovative biotech firms can focus their resources where they belong – in research and development that leads to breakthrough medicines and cures, and job creation – rather than navigating an overly complicated regulatory process that discourages the innovation that leads to cures.

“This new legislation includes a provision to modernize the Accelerated Approval pathway to expedite the development of modern, targeted, and personalized therapies for patients suffering from serious and life-threatening diseases, while preserving robust standards for safety and effectiveness. The pathway would apply only to treatments for diseases or conditions that are serious or life-threatening.

“The TREAT Act also includes key elements to improve the operational excellence of the FDA and help the agency integrate the most modern tools and methodologies to ensure a science-based, patient-focused review process.

“It is simply unacceptable that in the United States, as patients suffer and die, the time to take a new drug from discovery to patient is 10 to 15 years. More, regulatory uncertainty is having a major negative impact on the private funding of biomedical innovation, deteriorating the ability of our member companies to deliver cures and new medicines. Sixty-one percent of venture capitalists now cite FDA regulatory challenges as having the highest impact on their investment decisions, and 40% expect to decrease investment in the development of new therapies.

“The need to reform the investment and regulatory environment for biotechnology innovation has never been more urgent. Only by transforming the policy environment can we develop new cures and medicines, grow a robust 21st century innovation economy, maintain our nation’s global leadership in biotechnology, continue to create high-paying jobs in the U.S. and prevent the tsunami of additional health care costs that will be associated with the aging baby-boomer population.

“We look forward to supporting efforts to pass the TREAT Act and ultimately tap into the enormous scientific potential that resides in the thousands of small, medium and large American biotech companies to develop products that save, extend and improve the quality of life for patients worldwide.”

Biotech companies hold the greatest promise for finding cures to life-threatening diseases. There are currently 800 new treatments being developed for cancer by biotech companies, 300 for heart disease, 200 for diabetes, and 100 for Alzheimer’s.

When biotech finds cures it saves lives and dollars. Reducing cancer death rates by just 10 percent would have a $4 trillion economic impact. Delaying the onset of Alzheimer’s by just five years could save up to $50 billion per year. (Source: Murphy, K.M. and R.H. Topel, 2003. “Measuring the Gains from Medical Research.” University of Chicago Press; Alzheimer’s Association.)

To learn more about how biotechnology is transforming our world, please visit http://www.biotech-now.org.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.

For more information:
Visit http://www.bio.org
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech

Upcoming BIO Events

BIO IP Counsels Committee Conference
April 16-18, 2012
Austin, TX

World Congress on Industrial Biotechnology & Bioprocessing
April 29-May 2, 2012
Orlando, FL

2012 BIO International Convention
June 18-21, 2012
Boston, MA

BIO Business Forum
June 18-21, 2012
Boston, MA

Continue reading here:
TREAT Act Offers Renewed Hope for Patients

February 13, 2012 - Scheduled for April 29 to May 2, World Congress on Industrial Biotechnology and Bioprocessing will feature 6 breakout session tracks, and investor sessions that will allow executives to make 25-min presentations on their technology development and business models. Breakout tracks will include Advanced Biofuel Technologies, Algae and Feedstock Crops, Renewable Chemical Platforms and Biobased Materials, Specialty Chemicals, Synthetic Biology and Metabolic Engineering, and Technical Presentations.

Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
USA

Press release date: February 9, 2012

World Congress on Industrial Biotechnology and Bioprocessing

WASHINGTON--Biofuel and renewable chemical company executives, scientists and government officials from around the globe will speak in breakout sessions at BIO's 9th annual World Congress on Industrial Biotechnology and Bioprocessing. BIO today announced online availability of a searchable schedule of the breakout session programming.

BIO's World Congress will feature six breakout session tracks over three days. More than 35 sessions will cover the latest progress in commercializing advanced biofuels, consumer benefits from renewable chemicals, company partnerships and more in industrial biotechnology. The full program of breakout panel sessions and speakers is now available.

The six tracks designed to keep you on the cutting edge of industrial biotech are:

Advanced Biofuel Technologies
Algae and Feedstock Crops
Renewable Chemical Platforms and Biobased Materials
Specialty Chemicals
Synthetic Biology and Metabolic Engineering
Technical Presentations
Technical Presentations is a new track for 2012 that will feature research papers with presentations by academics, private sector scientists and researchers.

Brent Erickson, executive vice president of BIO's Industrial & Environmental Section, said, "We are excited to bring this conference to Orlando to highlight the industry's growth, the importance of this industrial and environmental biotechnology for generating green jobs, making greener products and cleaner processes all aimed at building a biobased economy. The Congress features discussions of high profile topics and will provide company executives an unparalleled opportunity to network with their colleagues and learn about the latest developments in the field of industrial biotechnology and bioprocessing."

BIO's World Congress will also feature investor sessions and business partnering opportunities. The investor sessions will allow executives from companies seeking to raise investment capital to make formal 25-minute presentations on their technology development and business models to an elite audience of investors and analysts. The partnering sessions utilize a computer system that assists companies and investors alike in arranging confidential one-on-one meetings with other attendees. Last year BIO's One-on-One Partnering led to more than 500 business partnering meetings.

The world's largest industrial biotechnology conference for business leaders, investors, academics and policymakers in biofuels, biobased products, renewable chemicals, synthetic biology, food ingredients and biomass comes to Orlando, Fla., April 29 - May 2 at the Gaylord Palms Resort & Convention Center. Online registration for the conference is now open. Early bird registration ends Feb. 29, 2012. Please visit http://www.bio.org/worldcongress/ for additional information, or email worldcongress@bio.org.

Online pre-registration for reporters and editors is now open. All breakout and plenary sessions at the BIO World Congress on Industrial Biotechnology and Bioprocessing are open to attendance by members of the media. Complimentary media registration is available to editors and reporters with valid press credentials working full time for print, broadcast or web publications.

About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech NOW, an online portal and monthly newsletter chronicling "innovations transforming our world." Subscribe to BIOtech NOW.

See the original post here:
BIO's 9th Annual World Congress on Industrial Biotechnology and Bioprocessing in Orlando to ...

07-02-2012 00:37 Advanced Biotechnology Podcast 1.2 Presented by the Texas Education Agency. In this lesson, we explore the basic concepts of molecular biology, and compare and contrast the structure and function of prokaryotic and eukaryotic cells.

Link:
Cell Structure and Function - Advanced Biotechnology Podcast 1.2 - Video

CLEVELAND, Feb. 14, 2012 /PRNewswire/ -- Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies.  A clinical stage startup developing a therapy to increase muscle strength and improve the quality of life of muscular dystrophy patients, Milo is the 61st company in JumpStart's portfolio.  "There are limited treatment options for muscular dystrophy and approved therapies are inadequate or can cause significant side effects," says JumpStart's Mike Lang. "Since most muscular dystrophy patients are children, the medical community is interested in a safer and more targeted therapy."

Milo Biotechnology's lead product is an adeno-associated virus (AAV) delivered follistatin protein.  Follistatin inhibits the activity of myostatin, a protein that impedes muscle differentiation and growth.  That makes follistatin a very potent stimulator of muscle growth and prevention of muscle scarring after injury.  "The translational research team at the Research Institute at Nationwide Children's Hospital has harnessed the power of follistatin and increased its specificity for muscle," explains Al Hawkins, CEO of Milo Biotechnology and CEO-in-Residence at BioEnterprise in Cleveland. "The efficacy and safety results thus far have been remarkable." Pre-clinical studies in mice and non-human primates demonstrated considerable increases in muscle size and strength.  FDA approved the investigators' IND in October 2011 and a clinical trial evaluating the safety and efficacy of Milo's follistatin therapy began last month at Columbus-based Nationwide Children's Hospital, where the technology was developed.  The Phase I/II trial, funded by a grant from Parent Project Muscular Dystrophy, is enrolling patients with Becker muscular dystrophy and inclusion body myositis.

Milo Biotechnology was founded by Hawkins and one of the lead inventors of the follistatin technology, Brian Kaspar, PhD. 

MILO BIOTECHNOLOGY  Milo Biotechnology is a Cleveland-based company dedicated to improving the lives of patients with neuromuscular diseases.  Milo's early clinical stage follistatin program, exclusively licensed from Nationwide Children's Hospital, is designed to increase muscle size and strength.

JUMPSTART INC  JumpStart Inc. accelerates the successes of entrepreneurs, their companies, and the ecosystems supporting them. JumpStart has given intensive business assistance to more than 400 entrepreneurial clients and invested in 61 early stage Northeast Ohio companies. For more information, visit http://www.jumpstartinc.org and follow @JumpStartInc on Twitter.

Read this article:
JumpStart Invests $250,000 in Milo Biotechnology

Background:
There is currently considerable interest in developing renewable sources ofenergy. One strategy is the biological conversion of plant biomass to liquidtransportation fuel. Several technical hurdles impinge upon the economicfeasibility of this strategy, including the development of energy cropsamenable to facile deconstruction. Reliable assays to characterize feedstockquality are needed to measure the effects of pre-treatment and processingand of the plant and microbial genetic diversity that influence bioconversionefficiency.
Results:
We used the anaerobic bacterium Clostridium phytofermentans to develop arobust assay for biomass digestibility and conversion to biofuels. The assayutilizes the ability of the microbe to convert biomass directly into ethanol withlittle or no pre-treatment. Plant samples were added to an anaerobic minimalmedium and inoculated with C. phytofermentans, incubated for 3 days, afterwhich the culture supernatant was analyzed for ethanol concentration. Theassay detected significant differences in the supernatant ethanol from wildtypesorghum compared with brown midrib sorghum mutants previouslyshown to be highly digestible. Compositional analysis of the biomass beforeand after inoculation suggested that differences in xylan metabolism werepartly responsible for the differences in ethanol yields. Additionally, wecharacterized the natural genetic variation for conversion efficiency inBrachypodium distachyon and shrub willow (Salix spp.).
Conclusion:
Our results agree with those from previous studies of lignin mutants usingenzymatic saccharification-based approaches. However, the use of C.phytofermentans takes into consideration specific organismal interactions,which will be crucial for simultaneous saccharification fermentation orconsolidated bioprocessing. The ability to detect such phenotypic variationfacilitates the genetic analysis of mechanisms underlying plant feedstockquality.Source:
http://www.biotechnologyforbiofuels.com/rss/

06-02-2012 13:12 An introduction to BlueZone Biotechnology - 2012

See the original post:
BlueZone Biotechnology - Video

03-02-2012 23:42 Within the next two decades the population of the world is expected to climb to 8 billion people. Feed 8 Billion is a panel discussion where internationally recognized scientists address the possibility of biotechnology feeding the future population of the world. The event was co-sponsored by the Arizona State University Biotechnology Club and Campus Student Sustainability Initiatives. Moderator - Dr Jason Robert Panelists: Dr Charles Arntzen Dr Roberto Gaxiola Dr Ben Hurlbut Marci Baranski Dr Rolf Halden 7 PM, February 2nd 2012, ASU room BAC 116

See the rest here:
Feed 8 Billion - a Panel Discussion on Biotechnology in Agriculture part 2 - Video

13-12-2011 15:13 Details about Sunnyvale, California based biotech

Visit link:
PBS NOVA Documentary Demonstrates Arrayit Biotechnology - Video

28-11-2011 12:25

Continue reading here:
Rosalie Ellasus - Benefits from Biotechnology - Video

UC Davis and Cornell University have the approval for testing genetically engineered grapes in California. In this case no application or environmental assessments were undertaken for the permits and there were just notifications given by the institutes. As far as the field tests are concerned there seems to be a veil of secrecy surrounding them therefore grape growers are not aware regarding the measures which need to be taken for protecting their vineyards from genetic contamination which could dent their image and even cause huge losses if the customers shun genetically engineered products. USDA was even criticized for not paying attention towards the field trials being undertaken and the U.S. Inspector General report said: USDA lacks basic information about the field test sites it approves and is responsible for monitoring, including where and how the crops are being grown, and what becomes of them at the end of the field test. It was only last month when a federal judge ruling stated that USDA cannot give approval for new GE field trials without environmental assessments but this wont be applicable to the grape field tests which have been already given permission. Such secrecy is expected to cause huge problems in the future for GE foods and if proper study and transparency is not ensured then genetically modified food will have a tough time ahead. Via napavalleyregister

Source:
http://www.biotechblog.org/rss.xml

We were up till now aware of the fact that sexual reproduction was the only means of bringing life into this world but a group of microscopic organisms seems to have broken this fact. A recent study has found out that since the past forty million years Bdelloid rotifers were evolving without sex. These aquatic animals thrive in wet areas and are asexual. In this case the Bdelloid rotifers produce eggs which are genetic clones of the mother and above all there is no male species, just females out there doing their job. That sounds amazing!! We are all aware of the fact that asexual animals cannot evolve and mutate over a period of time but study of the fossil records of bdelloid rotifers has stated that their existence can be traced back to forty million years. Up till now it was thought that sexual reproduction was important for spitting into divergent species but this has shocked everybody and also left a question to be answered as to how these species have been able to diverge without the addition of any genetic material. Via cbc

Source:
http://www.biotechblog.org/rss.xml

Fund Profile & Information for IBB

iShares Nasdaq Biotechnology Index Fund is an exchange-traded fund incorporated in the USA. The Fund's objective seeks investment results that correspond to the performance of the Nasdaq Biotechnology Index. The Fund will concentrate its investments in companies primarily engaged in using biomedical research for the discovery or development of new treatments or cures for human disease.

Inception Date: 2001-02-09 Telephone: 1-415-597-2000 Managers: GREG SAVAGE Web Site: http://www.ishares.com Fundamentals for IBB NAV (on 2012-02-06) 121.9103 Assets (M) (on 2012-01-31) 1,683.8850 Shares out (M) 14.15 Market Cap (M) 1,724.74 % Premium -0.02 Average 52-Week % Premium -0.0079 Fund Leveraged N Dividends for IBB Dividend Type Income Dividend Frequency Quarter Last Dividend Net - Dividend Yield (ttm) 0.0119 Performance for IBB 1-Month +13.69% 1-Year +29.48% 3-Month +27.00% 3-Year +18.07% Year To Date +16.81% 5-Year +9.08% Expense Ratio 0.48 Top Fund Holdings for IBB Filing Date: 02/03/2012 Amgen Inc 2,016,922 139,732,356 8.256% Alexion Pharmaceuticals Inc 1,415,274 111,629,737 6.596% Gilead Sciences Inc 1,906,869 104,296,200 6.163% Celgene Corp 1,418,932 103,880,012 6.138% Regeneron Pharmaceuticals Inc 975,578 944,944,858 5.583% Biogen Idec Inc 685,802 83,585,548 4.939% Teva Pharmaceutical Industries 1,771,061 80,955,198 4.783% Perrigo Co 668,139 62,577,899 3.698% Vertex Pharmaceuticals Inc 1,460,207 53,706,413 3.173% Mylan Inc/PA 2,187,785 49,093,895 2.901%

More here:
Snapshot for iShares Nasdaq Biotechnology Index Fund (IBB)

South Korea is playing a risky game as it has given the permission for using human eggs in cloning research despite a high level scandal in their country which involved one of their top scientists admitting to his involvement in doctored research work. Hwang Woo-suk was the scientist who had claimed that he had cloned human embryos and extracted stem cells from them but it was found out that all his claims were false. What raised eyes were when eggs required for research were donated by a female scientist in his team and this questioned the ethics of such practice. This shameful incident caused Hwang Woo-suk to resign from his post at the Seoul National University and is now facing trial for misappropriation of government funds. In order to get over the shameful act the government has again given a go ahead to use of human eggs in cloning but this time with an act of caution and under a new set of guidelines has asked that researchers should only use eggs which are to be destroyed after fertility treatments or from other legal ways and a prior license would have to be obtained from the government for undertaking research. It seems this time South Korea wants to take no chances. Via theage

Source:
http://www.biotechblog.org/rss.xml

The Food and Drug Administration is facing criticism over its recent preliminary approval to food from cloned animals as a consumer group has charged the agency for using flawed analysis. According to the Center for Food Safety, the FDA could not find studies on milk or meat from clones and whether they’re safe and the agency relied on studies done on cloned animals and whether they appeared healthy. Claiming that the conclusions drawn by the FDA was based on ‘scant data from few peer-reviewed studies’, Charles Margulis, a spokesman for Center for Food Safety, said: There isn’t the science to show that these foods are safe. I think the agency was heavily influenced by the biotechnology industry. Though FDA was tight lipped, Val Giddings, a scientist who consults with biotechnology companies, has come forward in FDA’s defence. According to Giddings an exhaustive amount of peer-reviewed data was the base of the conclusion. Giddings said: There’s not a single shred of data to suggest that food derived from clones or their offspring is in any way unsafe. All of what FDA has done here has been completely transparent. The FDA found that food from clones and food from conventional livestock has no virtual difference between and therefore special labels for cloned food would be necessary. Center for Food Safety might be in the process of waging a war against the FDA but Dean Foods Co. of Dallas has already decided to go against the idea of cloned food. Nations biggest milk company has decided it would not sell milk from cloned cows. The company’s decision was influenced by various surveys suggesting the dislike for dairy products from clones by Americans. Source.

Source:
http://www.biotechblog.org/rss.xml

03-02-2012 22:01 Within the next two decades the population of the world is expected to climb to 8 billion people. Feed 8 Billion is a panel discussion where internationally recognized scientists address the possibility of biotechnology feeding the future population of the world. The event was co-sponsored by the Arizona State University Biotechnology Club and Campus Student Sustainability Initiatives. Moderator - Dr Jason Robert Panelists: Dr Charles Arntzen Dr Roberto Gaxiola Dr Ben Hurlbut Marci Baranski Dr Rolf Halden 7 PM, February 2nd 2012, ASU room BAC 116

Follow this link:
Feed 8 Billion - a Panel Discussion on Biotechnology in Agriculture part 1 - Video

31-01-2012 07:26

Continued here:
AcrivaUD Reviol Toric T MFM 611 IOL Implantation - VSY Biotechnology - Video

26-01-2012 23:29 Biotechnology Workshop for School Students at Dr. MGR University

More:
Biotechnology Workshop for School Students at Dr. MGR University - Video

NEW YORK, NY--(Marketwire -01/31/12)- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Reuters' 2012 biotech outlook says this could mean an even greater reliance upon drugs. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN - News) and ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/DNDN
http://www.fivestarequities.com/ANX

Gunderson Capital Management argues that part of biotech's rally is being driven by expectations that President Barack Obama's health care reform plan may be repealed. Earlier this month House Republicans pushed through a resolution in support of a Constitutional amendment that would repeal Obamacare. House Resolution 1003 asks Congress to call a constitutional convention to propose an amendment to repeal the Affordable Care Act, which is also set to be challenged before the Supreme Court this year.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

ADVENTRX's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel. In December ADVENTRX met with the U.S. Food and Drug Administration (FDA) to review development plans for ANX-188.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Follow this link:
Biotech Sector on the Upswing -- Dendreon and ADVENTRX Pharmaceuticals Looking Strong

25-01-2012 12:00 The Andalusian Centre for Nanomedicine and Biotechnology, BIONAND, is a mixed centre with stakes held by the Regional Ministry of Innovation, Science and Enterprise, the Regional Ministry of Health and the University of Malaga with the purpose to promote and encourage the development of an andalusian centre for excellence research in Nanomedicine.

See the original post here:
Andalusian Centre for Nanomedicine and Biotechnology, BIONAND - Video

NEW YORK, NY--(Marketwire -01/31/12)- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Reuters' 2012 biotech outlook says this could mean an even greater reliance upon drugs. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on BioSante Pharmaceuticals Inc. (NASDAQ: BPAX - News) and Cell Therapeutics, Inc. (NASDAQ: CTIC - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/BPAX
http://www.fivestarequities.com/CTIC

Gunderson Capital Management argues that part of biotech's rally is being driven by expectations that President Barack Obama's health care reform plan may be repealed. Earlier this month House Republicans pushed through a resolution in support of a Constitutional amendment that would repeal Obamacare. House Resolution 1003 asks Congress to call a constitutional convention to propose an amendment to repeal the Affordable Care Act, which is also set to be challenged before the Supreme Court this year.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. Earlier this month the company announced that, following discussions with the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), the CHMP may issue an opinion on CTI's Marketing Authorization Application for Pixuvri in mid-February. Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents.

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Read the original here:
Shares of BioSante and Cell Therapeutics on the Upswing as Biotech Sector Rallies